Table 1.
Demographic and clinical characteristics of study participants by RAS inhibitor use.
| Participant characteristics* | Total (n = 150) | RAS inhibitor users (n = 90) | RAS inhibitor nonusers (n = 60) |
|---|---|---|---|
| Demographics | |||
| Age at death, years | 86.6 (6.1) | 86.8 (5.9) | 86.3 (6.4) |
| Female, n (%) | 72.0 (48.0%) | 44.0 (48.9%) | 28.0 (46.7%) |
| Education, years | 18.2 (3.3) | 17.9 (3.0) | 18.5 (3.6) |
| Medical conditions | |||
| Diabetes, n (%)* | 75.0 (50.0%) | 54.0 (60.0%) | 21.0 (35.0%) |
| Hypertension, n (%)* | 105.0 (70.0%) | 73.0 (81.1%) | 32.0 (53.3%) |
| Coronary heart disease, n (%)* | 43.0 (28.7%) | 32.0 (35.6%) | 11.0 (18.3%) |
| Stroke, n (%) | 38.0 (25.3%) | 22.0 (24.4%) | 16.0 (26.7%) |
| Physical examination | |||
| Systolic blood pressure, mmHg | 123.3 (15.9) | 124.5 (16.6) | 121.68 (15.4) |
| Diastolic blood pressure, mmHg | 69.3 (8.3) | 67.1 (8.5) | 72.3 (7.4) |
| Body mass index, kg/m2 | 26.4 (5.7) | 26.6 (5.6) | 26.2 (5.9) |
Mean (SD) unless specified. An asterisk (*) indicates statistical significance (p < 0.05) between RAS inhibitor users and nonusers in a two‐sample t‐test or a Chi‐square test.